安徽医科大学学报
安徽醫科大學學報
안휘의과대학학보
ACTA UNIVERSITY MEDICINALIS ANHUI
2015年
2期
129-134,135
,共7页
蒋克国%王德光%周海胜%查晓军%张桂霞%金福泉%季爽%潘海峰%叶冬青%郝丽
蔣剋國%王德光%週海勝%查曉軍%張桂霞%金福泉%季爽%潘海峰%葉鼕青%郝麗
장극국%왕덕광%주해성%사효군%장계하%금복천%계상%반해봉%협동청%학려
狼疮性肾炎%人肾小管上皮细胞%SIGIRR%慢病毒载体%NF-κB%趋化因子
狼瘡性腎炎%人腎小管上皮細胞%SIGIRR%慢病毒載體%NF-κB%趨化因子
랑창성신염%인신소관상피세포%SIGIRR%만병독재체%NF-κB%추화인자
lupus nephritis%human renal tubular epithelial cells%SIGRR%lentiviral vector%NF-κB%chemokine
目的:建立稳定敲低单免疫球蛋白白介素1相关受体(SIGIRR)基因的人肾小管上皮细胞株(HKC),并初步研究其功能。方法针对SIGIRR基因的有效靶点设计shRNA序列,与 GV248-GFP-Puro 慢病毒载体连接产生重组体( GV248-GFP-Puro-shSIGIRR)。将测序验证正确的重组体与包装质粒(pMDL、pRev、pVSVG)共转染293T细胞进行病毒包装,收集病毒并感染HKC细胞。实时荧光定量PCR( qRT-PCR)和Western blot法分析检测HKC细胞中SIGIRR干涉效率。应用白细胞介素-1β( IL-1β)刺激成功敲低SIGIRR的HKC细胞及对照细胞, Western blot法检测其下游核转录因子NF-κB(p65)的磷酸化水平,qRT-PCR分析单核细胞趋化蛋白-1(MCP-1)、正常 T细胞表达和分泌的活化调节蛋白( RANTES) mRNA水平。结果成功构建重组慢病毒载体GV248-GFP-Puro-shSIGIRR。 qRT-PCR 和 Western blot 法均证实在HKC细胞中成功敲低SIGIRR的表达。此外, IL-1β刺激后,与对照细胞相比,敲低SIGIRR的HKC细胞( HKC/shSIGIRR)的p65磷酸化水平上调, MCP-1和 RANTES mR-NA表达水平升高。结论 HKC的炎症反应中,SIGIRR蛋白对Toll样受体/白介素1受体(TLR/IL-1R)通路起“刹车”作用。该研究为狼疮性肾炎的治疗提供了新的潜在的靶点。
目的:建立穩定敲低單免疫毬蛋白白介素1相關受體(SIGIRR)基因的人腎小管上皮細胞株(HKC),併初步研究其功能。方法針對SIGIRR基因的有效靶點設計shRNA序列,與 GV248-GFP-Puro 慢病毒載體連接產生重組體( GV248-GFP-Puro-shSIGIRR)。將測序驗證正確的重組體與包裝質粒(pMDL、pRev、pVSVG)共轉染293T細胞進行病毒包裝,收集病毒併感染HKC細胞。實時熒光定量PCR( qRT-PCR)和Western blot法分析檢測HKC細胞中SIGIRR榦涉效率。應用白細胞介素-1β( IL-1β)刺激成功敲低SIGIRR的HKC細胞及對照細胞, Western blot法檢測其下遊覈轉錄因子NF-κB(p65)的燐痠化水平,qRT-PCR分析單覈細胞趨化蛋白-1(MCP-1)、正常 T細胞錶達和分泌的活化調節蛋白( RANTES) mRNA水平。結果成功構建重組慢病毒載體GV248-GFP-Puro-shSIGIRR。 qRT-PCR 和 Western blot 法均證實在HKC細胞中成功敲低SIGIRR的錶達。此外, IL-1β刺激後,與對照細胞相比,敲低SIGIRR的HKC細胞( HKC/shSIGIRR)的p65燐痠化水平上調, MCP-1和 RANTES mR-NA錶達水平升高。結論 HKC的炎癥反應中,SIGIRR蛋白對Toll樣受體/白介素1受體(TLR/IL-1R)通路起“剎車”作用。該研究為狼瘡性腎炎的治療提供瞭新的潛在的靶點。
목적:건립은정고저단면역구단백백개소1상관수체(SIGIRR)기인적인신소관상피세포주(HKC),병초보연구기공능。방법침대SIGIRR기인적유효파점설계shRNA서렬,여 GV248-GFP-Puro 만병독재체련접산생중조체( GV248-GFP-Puro-shSIGIRR)。장측서험증정학적중조체여포장질립(pMDL、pRev、pVSVG)공전염293T세포진행병독포장,수집병독병감염HKC세포。실시형광정량PCR( qRT-PCR)화Western blot법분석검측HKC세포중SIGIRR간섭효솔。응용백세포개소-1β( IL-1β)자격성공고저SIGIRR적HKC세포급대조세포, Western blot법검측기하유핵전록인자NF-κB(p65)적린산화수평,qRT-PCR분석단핵세포추화단백-1(MCP-1)、정상 T세포표체화분비적활화조절단백( RANTES) mRNA수평。결과성공구건중조만병독재체GV248-GFP-Puro-shSIGIRR。 qRT-PCR 화 Western blot 법균증실재HKC세포중성공고저SIGIRR적표체。차외, IL-1β자격후,여대조세포상비,고저SIGIRR적HKC세포( HKC/shSIGIRR)적p65린산화수평상조, MCP-1화 RANTES mR-NA표체수평승고。결론 HKC적염증반응중,SIGIRR단백대Toll양수체/백개소1수체(TLR/IL-1R)통로기“찰차”작용。해연구위랑창성신염적치료제공료신적잠재적파점。
Objective To establish single immunoglobin IL-1-related receptor ( SIGIRR) stable knockdown human renal tubular epithelial cells ( HKC) and explore its function. Methods Designed the effective targeted shRNA se-quences for the SIGIRR gene, and then connected with the GV248-GFP-Puro to produce recombinant lentiviral vec-tor ( GV248-GFP-Puro-shSIGIRR ) . The corrected recombinants, identified by sequenced, were transfected into 293T cells with packaging plasmids (pMDL, pRev, pVSVG) for virus packaging. HKC cells were then infected by packaged viruses. Quantitative real-time PCR( qRT-PCR) and Western blot were used to detect the interference effi-ciency of SIGIRR in HKC cells. SIGIRR stable knockdown HKC cells ( HKC/shSIGIRR ) and the control cells were induced by IL-1β, then the downstream nuclear transcription factor, the phosphorylated NF-κB ( p65 ) were detected by Western blot. The mRNA expression levels of chemokine monocyte chemotactic protein 1 (MCP-1) and regulated upon activation normal T cell expressed and secreted factor ( RANTES) were analyzed by qRT-PCR.Results The results showed that the recombinant lentiviral vector GV248-GFP-Puro-shSIGIRR was successfully constructed. qRT-PCR and Western blot confirmed that SIGIRR was knockdown in HKC cells. Moreover, the re-sults also showed that compared with the control cells, the phosphorylated NF-κB (p65) and the mRNA levels of MCP-1 and RANTES were significantly increased in HKC/shSIGIRR cells by being stimulated with IL-1β. Conclu-sion The results suggest that SIGIRR acts as a“brake” of inflammatory reaction in Toll-like receptor/IL-1 recep-tor (TLR/IL-1R) pathway in HKC cells. The study may provide a potential new target for the treatment of Lupus nephritis.